Narcotic Drugs Market Report 2026

The narcotic drugs market size has grown steadily in recent years. It will grow from $14.71 billion in 2025 to $15.32 billion in 2026 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increasing prevalence of chronic pain, widespread opium cultivation, rising incidence of cancer-related pain, traditional reliance on hospital pharmacies, high prevalence of cough and diarrhea conditions.

The narcotic drugs market size is expected to see strong growth in the next few years. It will grow to $18.79 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to growing demand for abuse-deterrent formulations, expansion of online pharmacy channels, advancements in synthetic narcotics production, rising focus on personalized pain management, increasing regulatory approvals for new narcotic drugs. Major trends in the forecast period include rise in prescription drug monitoring programs, growth of pain management therapies, increasing abuse-deterrent formulations, expansion of specialty pharmacies, development of synthetic narcotics.

The rising incidence of chronic diseases is expected to drive the growth of the narcotic drug market in the coming years. Chronic diseases are illnesses that last three months or more and can progressively worsen over time. Narcotic drugs are used to manage chronic conditions by alleviating pain associated with cancer, chronic pain syndrome, terminal illnesses, and severe arthritis. For instance, in June 2024, the National Health Service, a UK-based government department, reported that in 2023, over half a million (549,000) additional individuals in England were identified at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a notable increase from 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the rising incidence of chronic diseases is driving growth in the narcotic drug market.

Major companies operating in the narcotic drug market are increasingly focusing on product development and innovation to provide reliable solutions to patients and strengthen their market position. For instance, in May 2023, Indivior PLC, a US-based pharmaceutical company, launched OPVEE (nalmefene) nasal spray, an opioid overdose rescue medication for natural and synthetic opioids such as fentanyl. It is recommended for immediate treatment of known or suspected opioid overdoses in adults and pediatric patients aged 12 years and older, based on the presence of respiratory and central nervous system depression.

In March 2023, Indivior PLC, a US-based pharmaceutical company, acquired Opiant Pharmaceuticals Inc. for $145 million. Through this acquisition, Indivior PLC aims to strengthen its addiction treatment and science portfolio, particularly with OPNT003, an investigational opioid overdose therapy designed to address the current surge of US opioid overdoses caused by potent synthetic opioids such as fentanyl. Opiant Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the development and manufacture of narcotic drugs.

Major companies operating in the narcotic drugs market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Novartis AG, AstraZeneca PLC, Sanofi S.A., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Purdue Pharma LP, Hikma Pharmaceuticals Plc, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals, Alvogen Inc., Indivior Inc., Impax Laboratories Inc., Collegium Pharmaceutical Inc., Lannett Co Inc., Par Pharmaceutical Inc., West-Ward Pharmaceuticals Corp.

Asia-Pacific was the largest region in the narcotic drugs market in 2025. The regions covered in the narcotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the narcotic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the narcotic drugs market by increasing the cost of importing raw materials and active pharmaceutical ingredients (APIs), particularly in semi-synthetic and synthetic drug segments. This has affected manufacturing and supply chains across North America and Europe, where hospitals and specialty clinics are major consumers. While tariffs have temporarily raised production costs, they have also encouraged local sourcing, domestic production, and innovation in synthetic narcotic formulations, potentially strengthening regional supply resilience.

The narcotic drugs market research report is one of a series of new reports that provides narcotic drugs market statistics, including narcotic drugs industry global market size, regional shares, competitors with a narcotic drugs market share, detailed narcotic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the narcotic drugs industry. This narcotic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A narcotic drug is a type of medication that acts on the central nervous system to induce sleepiness, relieve pain, produce euphoria, and sometimes cause hallucinations. Narcotic drugs are usually derived from the opium poppy plant but can also be synthetically manufactured.

The main types of narcotic drugs include opium, heroin, codeine, oxycodone, and others. Opium is a bitter, brownish, addictive substance obtained from the dried latex of immature seed capsules of the opium poppy. These drugs can originate from natural, semi-synthetic, or synthetic sources and are used for various indications such as pain management, cough, diarrhea, dysentery, asthma, and others. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by various end users such as hospitals, homecare providers, specialty clinics, and others.

The narcotic drug market consists of sales of ketobemidone, pethidine, tolidine, and trimeperidine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.